Setting for "Normal" Serum Ferritin Levels in Patients with Transfusion-Dependent Thalassemia: Our Current Strategy

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Dec 24

PMID 34945281

Citations 6

Authors

Anna Spasiano

Antonella Meloni

Silvia Costantini

Emilio Quaia

Filippo Cademartiri

Patrizia Cinque

Alessia Pepe

Paolo Ricchi

Affiliations

Soon will be listed here.

Abstract

This cross-sectional study aimed to establish the association between serum ferritin levels and organ iron overload (IO) and overall morbidity in transfusion-dependent thalassemia (TDT) patients. One hundred and three TDT patients (40.03 ± 9.15 years; 57.3% females) with serum ferritin < 2500 ng/mL were included. IO was assessed by T2* magnetic resonance imaging. Three groups were identified based on mean serum ferritin levels: <500 ng/mL (group 0; N = 32), 500-1000 ng/mL (group 1; N = 43), and 1000-2500 ng/mL (group 2; N = 28). All demographic and biochemical parameters were comparable among the three groups, with the exception of the triglycerides being significantly lower in group 0 than in group 2. No difference was found in the frequency of hepatic, endocrine, and cardiac complications. Hepatic IO was significantly less frequent in group 0 versus both groups 1 and 2. No patient with a serum ferritin level < 500 ng/mL had significant myocardial IO and alterations in the main hematological parameters. No difference in the distribution of the different chelation regimens was found. Serum ferritin < 500 ng/mL appears to be achievable and safe for several TDT patients. This target is associated with the absence of significant cardiac iron and significantly lower hepatic IO and triglycerides that are well-demonstrated markers for cardiac and liver complications.

Citing Articles

Renal Findings in Patients with Thalassemia at Abdominal Ultrasound: Should We Still Talk about "Incidentalomas"? Results of a Long-Term Follow-Up.

Fatigati C, Meloni A, Costantini S, Spasiano A, Ascione F, Cademartiri F Diagnostics (Basel). 2024; 14(18).

PMID: 39335726 PMC: 11431600. DOI: 10.3390/diagnostics14182047.

Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.

Ricchi P, Meloni A, Pistoia L, Gamberini M, Cuccia L, Allo M Blood Transfus. 2023; 22(1):75-85.

PMID: 37146300 PMC: 10812892. DOI: 10.2450/BloodTransfus.485.

Optimized serum ferritin prediction of iron overload in transfusion-dependent thalassemia: likelihood ratio and age-adjustment approach.

Kurban L, Almarri B, Alshamsi M, Abdelrahman S, Alwahshi S, Alhorani Q Ann Saudi Med. 2023; 43(2):90-96.

PMID: 37031371 PMC: 10082945. DOI: 10.5144/0256-4947.2023.90.

Longitudinal study of ICET-A on glucose tolerance, insulin sensitivity and β-cell secretion in eleven β-thalassemia major patients with mild iron overload.

De Sanctis V, Soliman A, Daar S, Tzoulis P, Di Maio S, Kattamis C Acta Biomed. 2023; 94(1):e2023011.

PMID: 36786253 PMC: 9987494. DOI: 10.23750/abm.v94i1.14000.

Glucose Homeostasis and Assessment of β-Cell Function by 3-hour Oral Glucose Tolerance (OGTT) in Patients with β-Thalassemia Major with Serum Ferritin below 1,000 ng/dL: Results from a Single ICET-A Centre.

De Sanctis V, Soliman A, Daar S, Tzoulis P, Di Maio S, Kattamis C Mediterr J Hematol Infect Dis. 2023; 15(1):e2023006.

PMID: 36660350 PMC: 9833310. DOI: 10.4084/MJHID.2023.006.

References

Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V . The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009; 11:20. PMC: 2713224. DOI: 10.1186/1532-429X-11-20. View

. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2004; 921:1-164, back cover. View

Pennell D, Porter J, Piga A, Lai Y, El-Beshlawy A, Belhoul K . A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014; 123(10):1447-54. PMC: 3945858. DOI: 10.1182/blood-2013-04-497842. View

Meloni A, Positano V, Pepe A, Rossi G, DellAmico M, Salvatori C . Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients. Magn Reson Med. 2010; 64(1):211-9. DOI: 10.1002/mrm.22410. View

Noetzli L, Mittelman S, Watanabe R, Coates T, Wood J . Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2011; 87(2):155-60. DOI: 10.1002/ajh.22223. View

Taher A, Musallam K, Cappellini M . β-Thalassemias. N Engl J Med. 2021; 384(8):727-743. DOI: 10.1056/NEJMra2021838. View

Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V . Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2009; 148(3):466-75. DOI: 10.1111/j.1365-2141.2009.07970.x. View

Buxton A, Calkins H, Callans D, DiMarco J, Fisher J, Greene H . ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to.... Circulation. 2006; 114(23):2534-70. DOI: 10.1161/CIRCULATIONAHA.106.180199. View

Ricchi P, Meloni A, Spasiano A, Costantini S, Pepe A, Cinque P . The impact of liver steatosis on the ability of serum ferritin levels to be predictive of liver iron concentration in non-transfusion-dependent thalassaemia patients. Br J Haematol. 2018; 180(5):721-726. DOI: 10.1111/bjh.15083. View

10.

Meloni A, De Marchi D, Positano V, Neri M, Mangione M, Keilberg P . Accurate estimate of pancreatic T2* values: how to deal with fat infiltration. Abdom Imaging. 2015; 40(8):3129-36. DOI: 10.1007/s00261-015-0522-9. View

11.

Positano V, Pepe A, Santarelli M, Scattini B, De Marchi D, Ramazzotti A . Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed. 2007; 20(6):578-90. DOI: 10.1002/nbm.1121. View

12.

Meloni A, Rienhoff Jr H, Jones A, Pepe A, Lombardi M, Wood J . The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. Br J Haematol. 2013; 161(6):888-91. PMC: 3672338. DOI: 10.1111/bjh.12296. View

13.

Ponticelli C, Musallam K, Cianciulli P, Cappellini M . Renal complications in transfusion-dependent beta thalassaemia. Blood Rev. 2010; 24(6):239-44. DOI: 10.1016/j.blre.2010.08.004. View

14.

Meloni A, Restaino G, Missere M, De Marchi D, Positano V, Valeri G . Pancreatic iron overload by T2* MRI in a large cohort of well treated thalassemia major patients: can it tell us heart iron distribution and function?. Am J Hematol. 2015; 90(9):E189-90. DOI: 10.1002/ajh.24081. View

15.

Positano V, Meloni A, Santarelli M, Gerardi C, Bitti P, Cirotto C . Fast generation of T2* maps in the entire range of clinical interest: application to thalassemia major patients. Comput Biol Med. 2014; 56:200-10. DOI: 10.1016/j.compbiomed.2014.10.020. View

16.

Pepe A, Meloni A, Pistoia L, Cuccia L, Gamberini M, Lisi R . MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. Br J Haematol. 2018; 183(5):783-795. DOI: 10.1111/bjh.15595. View

17.

Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M, Del Vecchio G . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-93. View

18.

Tanner M, Galanello R, Dessi C, Smith G, Westwood M, Agus A . A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007; 115(14):1876-84. DOI: 10.1161/CIRCULATIONAHA.106.648790. View

19.

Restaino G, Meloni A, Positano V, Missere M, Rossi G, Calandriello L . Regional and global pancreatic T*2 MRI for iron overload assessment in a large cohort of healthy subjects: normal values and correlation with age and gender. Magn Reson Med. 2011; 65(3):764-9. DOI: 10.1002/mrm.22640. View

20.

. Standards of medical care in diabetes--2011. Diabetes Care. 2011; 34 Suppl 1:S11-61. PMC: 3006050. DOI: 10.2337/dc11-S011. View